Manu Chakravarthy
Technik-/Wissenschafts-/F&E-Leiter bei Carmot Therapeutics, Inc.
Aktive Positionen von Manu Chakravarthy
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2021 | - |
Karriereverlauf von Manu Chakravarthy
Ehemalige bekannte Positionen von Manu Chakravarthy
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| AXCA HEALPAR | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2017 | 05.03.2021 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01.08.2015 | 01.06.2017 |
Ausbildung von Manu Chakravarthy
| Saint John's University | Undergraduate Degree |
| University of Texas Graduate School of Biomedical Sciences | Doctorate Degree |
| The University of Texas Medical School At Houston | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 2 |
| Corporate Officer/Principal | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| AXCA HEALPAR | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Börse
- Insiders
- Manu Chakravarthy
- Erfahrung
